Cohort profile: The Swiss HIV cohort study

International Journal of Epidemiology

Volumn 39, Issue 5, 2010, Pages 1179-1189

  Schoeni Affolter, Franziska ^a   Ledergerber, Bruno ^a   Rickenbach, Martin ^a   Rudin, Christoph ^a   Günthard, Huldrych F ^a   Telenti, Amalio ^a   Furrer, Hansjakob ^a   Yerly, Sabine ^a   Francioli, Patrick ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DISEASE PREVALENCE; EPIDEMIOLOGY; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; RISK FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; DISEASE TRANSMISSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SEXUAL BEHAVIOR; SWITZERLAND; VERTICAL TRANSMISSION; VIRUS CELL INTERACTION;

ADOLESCENT; ADULT; AGED; AGING; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT DROPOUTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; SWITZERLAND;

SWITZERLAND;

EID: 78149370844     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyp321     Document Type: Article

References (104)

1. Fellay J, Boubaker K, Ledergerber B et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-27.
2. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997;315:1194-99.
3. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-68.
4. Hirsch MS, Gunthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47:266-85.
5. Yerly S, von Wyl V, Ledergerber B et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007;21:2223-29.
6. von Wyl V, Yerly S, Burgisser P et al. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009;48:979-87.
7. Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS ONE 2007;2:e173.
8. von Wyl V, Yerly S, Boni J et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007;167: 1782-90.
9. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-5.
10. Furrer H, Telenti A, Rossi M, Ledergerber B. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 2000;14:1409-12.
11. Furrer H, Egger M, Opravil M et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999;340:1301-6.
12. Clifford GM, Polesel J, Rickenbach M et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-32.
13. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001;344:168-74.
14. Elzi L, Schlegel M, Weber R et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007;44: 94-102.
15. Kirk O, Reiss P, Uberti-Foppa C et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002;137: 239-50.
16. Zellweger C, Opravil M, Bernasconi E et al. Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study. AIDS 2004;18:2047-53.
17. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207; quiz CE1-4.
18. Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-47.
19. Arab-Alameddine M, Di Iulio J, Buclin T et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009;85:485-94.
20. Arnedo M, Taffe P, Sahli R et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007;17:755-64.
21. Felley C, Morris MA, Wonkam A et al. The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS 2004;18: 1521-27.
22. Rotger M, Taffe P, Bleiber G et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005;192:1381-86.
23. Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007;81:557-66.
24. Kind C, Rudin C, Siegrist CA et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS 1998;12:205-10.
25. Lorenzi P, Spicher VM, Laubereau B et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241-47.
26. Thorne C, Rudin C, Newell M-L et al. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14:2913-20.
27. Glass TR, De Geest S, Hirschel B et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008;13: 77-85.
28. von Wyl V, Yerly S, Boni J et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 2008;46:1299-309.
29. Scherrer AU, Hasse B, von Wyl V et al. Estimate of etravirine activity in drug naïve and drug experienced patients according to genotypic drug resistance information: The Swiss HIV Cohort Study (SHCS). HIV Med 2009 [Epub 1 September 2009].
30. Yerly S, Junier T, Gayet-Ageron A et al. The phylogeny of newly diagnosed HIV-1 infection reveals transmission clusters contributing to primary drug resistance. AIDS 2009;23:1415-23.
31. Gupta R, Hill A, Sawyer A et al. The intensity of virological monitoring is associated with resistance to first line HAART in HIV-1 infected adults under the WHO public health approach to antiretroviral therapy: a systematic analysis of cohort and trial data. Lancet Infect Dis 2009; 9:409-17.
32. Bellini C, Keiser O, Chave JP et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009;10:12-18.
33. Fux CA, Rauch A, Simcock M et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008;13: 1077-82.
34. Fux CA, Simcock M, Wolbers M et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007;12:1165-73.
35. Keiser O, Fellay J, Opravil M et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther 2007; 12:1157-64.
36. Rudin C, Burri M, Shen Y, Rode R, Nadal D. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J 2008;27:431-37.
37. Wunder DM, Bersinger NA, Fux CA et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007;12:261-65.
38. Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy. AIDS 2007;21:939-46.
39. Khanna N, Opravil M, Furrer H et al. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008;47: 1093-101.
40. Mocroft A, Ledergerber B, Zilmer K et al. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA riskscore. AIDS 2007;21:1867-75.
41. Taffe P, Bucher HC, Flepp M, Battegay M. Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era. AIDS 2007;21:537-38.
42. Vernazza P, Daneel S, Schiffer V et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007;21:1309-15.
43. Vo TT, Ledergerber B, Keiser O et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008;197:1685-94.
44. Wolbers M, Battegay M, Hirschel B et al. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 2007;12:889-97.
45. Wolbers M, Bucher HC, Furrer H et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 2008;9: 397-405.
46. Wolbers M, Opravil M, von Wyl V et al. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. AIDS 2007;21:2201-7.
47. Dunn D, Woodburn P, Duong T et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008;197: 398-404.
48. Rauch A, Nolan D, Thurnheer C et al. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir Ther 2008;13:1019-28.
49. Rauch A, Rickenbach M, Weber R et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395-402.
50. Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371: 1417-26.
51. Periard D, Cavassini M, Taffe P et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis 2008;46:761-67.
52. Nguyen A, Calmy A, Schiffer V et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008;9:142-50. THE SWISS HIV COHORT STUDY 1187.
53. Ledergerber B, Furrer H, Rickenbach M et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007;45:111-19.
54. Glass TR, Weber R, Vernazza PL et al. Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV Clin Trials 2007;8:77-85.
55. Sterne JA, May M, Bucher HC et al. HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med 2007;261:255-67.
56. Wunder DM, Fux CA, Bersinger NA et al. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study. HIV Med 2008;9:427-32.
57. Garbino J, Inoubli S, Mossdorf E et al. Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection. AIDS 2008;22:701-5.
58. Hoffmann M, Reichmuth M, Fantelli K et al. Conventional tuberculin skin testing versus T-cell-based assays in the diagnosis of latent tuberculosis infection in HIV-positive patients. AIDS 2007;21:390-92.
59. Rauch A, Gaudieri S, Evison J et al. Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antivir Ther 2008;13:455-60.
60. Gasser O, Bihl FK, Wolbers M et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007;4:e96.
61. Khanna N, Wolbers M, Mueller NJ et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 2009;83:4404-11.
62. Clifford GM, Rickenbach M, Polesel J et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008;22:2135-41.
63. El Amari EB, Toutous-Trellu L, Gayet-Ageron A et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008;22: 1019-28.
64. Franceschi S, Maso LD, Rickenbach M et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-4.
65. Gasser O, Wolbers M, Steffen I, Hirsch HH, Battegay M, Hess C. Increased Epstein-Barr virus-specific antibodylevels in HIV-infected individuals developing primary central nervous system lymphoma. AIDS 2007;21: 1664-66.
66. Polesel J, Clifford GM, Rickenbach M et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008;22:301-6.
67. Simcock M, Blasko M, Karrer U et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007;12:931-39.
68. Weiser B, Philpott S, Klimkait T et al. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008;22:469-79.
69. Bochud PY, Hersberger M, Taffe P et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007;21:441-46.
70. Colombo S, Rauch A, Rotger M et al. The HCP5 singlenucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008;198:864-67.
71. Rauch A, Nolan D, Furrer H et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis 2008;46: 1921-25.
72. Rotger M, Colombo S, Furrer H, Decosterd L, Buclin T, Telenti A. Does tenofovir influence efavirenz pharmacokinetics? Antivir Ther 2007;12:115-18.
73. Rotger M, Saumoy M, Zhang K et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics 2007;17:885-90.
74. Frater AJ, Brown H, Oxenius A et al. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J Virol 2007;81:6742-51.
75. Joos B, Fischer M, Kuster H et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 2008;105: 16725-30.
76. Kaiser P, Joos B, Niederost B, Weber R, Gunthard HF, Fischer M. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol 2007;81:9693-706.
77. Muller V, von Wyl V, Yerly S et al. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS 2009;23:1269-76.
78. Brossard P, Boulvain M, Coll O et al. Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study. AIDS 2008;22:2013-17.
79. Kahlert C, Rudin C, Kind C. Sudden infant death syndrome in infants born to HIV-infected and opiate-using mothers. Arch Dis Child 2007;92:1005-8.
80. Keiser O, Gayet-Ageron A, Rudin C et al. Antiretroviral treatment during pregnancy. AIDS 2008;22:2323-30.
81. Gredig D, Niderost S, Rickenbach M. Parents living with HIV in a high-income country: do patients need specific support? Swiss Med Wkly 2008;138:38-46.
82. Sendi P, Brouwer WB, Bucher HC, Weber R, Battegay M. When time is more than money: the allocation of time between work and leisure in HIV-infected patients. Soc Sci Med 2007;64:2355-61.
83. Conen A, Fehr J, Glass TR et al. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antivir Ther 2009;14:349-57.
84. Staehelin C, Rickenbach M, Low N et al. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003;17:2237-44.
85. Weber R, Huber M, Rickenbach M et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med 2009;10: 407-16.
86. Taffe P, May M. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 2008;27:4835-53.
87. Keiser O, Orrell C, Egger M et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008;5:e148.
88. Sabin CA, d'Arminio Monforte A, Friis-Moller N et al. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008;46:1101-10.
89. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
90. Mugavero MJ, May M, Harris R et al. Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice? AIDS 2008;22:2481-92.
91. Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008;22: 2441-50.
92. Monforte A, Abrams D, Pradier C et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008;22: 2143-53.
93. Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L et al. Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analoguebased regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. J Infect Dis 2007;196: 1180-90.
94. ART-C. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr 2007;46: 607-15.
95. De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31: 1224-29.
96. Martin MP, Qi Y, Gao X et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007;39:733-40.
97. ART-C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372: 293-99.
98. Mocroft A, Phillips AN, Gatell J et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007;370:407-13.
99. May M, Sterne JA, Sabin C et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-97.
100. Damond F, Benard A, Ruelle J et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008;46:2088-91.
101. Mocroft A, Staszewski S, Weber R et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviralnaive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007;12: 325-33.
102. Brinkhof MW, Egger M, Boulle A et al. Tuberculosis after initiation of antiretroviral therapy in low-income THE SWISS HIV COHORT STUDY 1189 and high-income countries. Clin Infect Dis 2007;45: 1518-21.
103. SMART/INSIGHT, D:A:D. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-24.
104. Veit O, Niedrig M, Chapuis-Taillard C et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009;48: 659-66.